Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Meta-Analysis of Randomized Controlled Trials on the Efficacy of Direct Oral Anticoagulants in Left Ventricular Thrombosis: An Updated Perspective
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 10 – DOENÇA CARDIOVASCULAR EM DOENTES ONCOLÓGICOS E ANTICOAGULAÇÃO
Speaker:
Bernardo Lisboa Resende
Congress:
CPC 2025
Topic:
L. Cardiovascular Pharmacology
Theme:
31. Pharmacology and Pharmacotherapy
Subtheme:
31.1 Cardiovascular Pharmacotherapy
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Bernardo Manuel Lisboa Resende; Mariana Simões; Luisa Gomes Rocha; Tomás Carlos; Mafalda Griné; Gonçalo Batista; Ana Luísa Silva; Tatiana Santos; Rafaela Fernandes; Gonçalo Costa; João Gameiro; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Background:</span></strong><span style="color:black"> Left ventricular thrombus (LVT) secondary to left ventricular dysfunction represents a clinical challenge with profound implications for patient morbidity and mortality. A substantial body of evidence has emerged on this topic. However, much of it is derived from observational studies, which lack randomization and consequently impose significant limitations. In line with this, the 2023 guidelines for Acute Coronary Syndrome recommend the use of direct oral anticoagulants (DOACs) or warfarin for LVT management, yet this recommendation is based on a single randomized controlled trial (RCT) with limited data, hindering critical analysis.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Purpose:</span></strong><span style="color:black"> Conduct a systematic review and meta-analysis to assess the efficacy and safety profile of DOACs compared with warfarin in the management of LVT.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Methods:</span></strong><span style="color:black"> We systematically searched the Cochrane Controlled Register of Trials, EMBASE, and PubMed, focusing exclusively on RCTs. We sought studies comparing the use of DOACs, without restrictions on active principles, against warfarin. The primary outcomes were overall thrombus resolution and major bleeding events, while secondary endpoints included all-cause mortality and stroke. We pooled dichotomous data using odds ratios (OR) to describe effect sizes, employing the Mantel-Haenszel procedure within a random-effects model, with a 95% confidence interval. Heterogeneity was assessed statistically using the I² index (<25% low, 25%-50% moderate, >50% high heterogeneity).</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Results: </span></strong><span style="background-color:white"><span style="color:black">Of the 290 records identified, 7 studies were included, providing data on 530 patients. Our meta-analysis revealed no significant differences in overall LVT resolution (pooled OR 1.52 [0.97, 2.36], P = 0.92, I² = 0), despite a trend favoring the DOAC group. Additionally, no differences were observed between groups regarding major bleeding events (pooled OR 0.51 [0.17, 1.52], P = 0.47, I² = 0). Furthermore, no differences were found regarding all-cause mortality (pooled OR 0.70 [0.20, 2.42], P = 0.57, I² = 0) or stroke (pooled OR 0.56 [0.12, 2.57], P = 0.42, I² = 0).</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong>Conclusions: </strong><span style="background-color:white"><span style="color:black">This meta-analysis indicates that DOACs are effective and safe alternatives to warfarin in the management of LVT. The advantages of DOACs, including their oral administration and ease of management, make them a more favorable option in contemporary clinical practice. Nevertheless, further large RCTs are necessary to further elucidate their role and optimize treatment strategies in this patient population.</span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site